{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-23-000063","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.119577+00:00","generated_at":"2026-06-09T07:49:41.567724+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PTC Therapeutics Q3 total revenues $196.6M (-9% YoY), net loss $133M; updates pipeline timelines","bullets":["DMD franchise revenue $136M in Q3; full-year 2023 DMD guidance raised to $565-595M.","Translarna net revenue $69M; CHMP re-examination expected Jan 2024; FDA type C meeting in Q4 2023.","Sepiapterin NDA submission for PKU delayed to no later than Q3 2024; MAA to EMA in H1 2024.","PTC518 HD trial enrollment ongoing; FDA requires 6-month safety data for US dosing.","Total 2023 revenue guidance $940M-$1.0B; GAAP R&D+SG&A expenses $915-965M."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-23-000063","json":"https://secwatch.observer/filing/0001070081-23-000063.json","markdown":"https://secwatch.observer/filing/0001070081-23-000063.md","text":"https://secwatch.observer/filing/0001070081-23-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000063/0001070081-23-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000063/tmb-20231026x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T07:49:41.567724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26d3a5e049928e3c06653ea0224a4da4ecccff28","claim":"PTC THERAPEUTICS, INC. reported the third quarter ending September 30, 2023 results: revenue $196.6 million. Guidance reaffirmed.","evidence_excerpt":"Total revenues were $196.6 million for the third quarter of 2023, compared to $217.1 million for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000063/0001070081-23-000063-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ending September 30, 2023"},{"label":"Revenue","value":"$196.6 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}